logo

PRQR

ProQR Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.06 / 10
Netural

Analysis concludes mixed fundamental quality (4.1/10). Favorable components: Revenue-MV and Profit-MV, balanced by issues in Current assets turnover ratio and Fixed assets turnover ratio. Investment recommendation: defensive.

Fundamental(4.06)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-2.46
Score2/3
Weight18.39%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight7.08%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight16.19%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight12.07%
1M Return7.79%
PB-ROE
Value0.79
Score1/3
Weight11.14%
1M Return7.02%
Current assets turnover ratio
Value0.08
Score0/3
Weight-2.21%
1M Return-1.88%
Fixed assets turnover ratio
Value0.83
Score1/3
Weight-1.91%
1M Return-1.64%
Asset-MV
Value-0.50
Score2/3
Weight27.53%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight12.08%
1M Return7.73%
Net profit / Total profit (%)
Value100.05
Score0/3
Weight-0.36%
1M Return-0.30%
Is PRQR fundamentally strong?
  • PRQR scores 4.06/10 on fundamentals and holds a Fair valuation at present. Backed by its -45.68% ROE, -276.86% net margin, -3.35 P/E ratio, 2.36 P/B ratio, and -29.75% earnings growth, these metrics solidify its Netural investment rating.